Hepatology:在美国,慢性乙型肝炎患者的并发症和发病年龄

2018-09-25 MedSci MedSci原创

相比病例对照,被保险的CHB患者年龄较大,并发症越多,并且有较高的发病率和患病率。

研究背景:慢性乙型肝炎(CHB)并发症数据有限。使用保险索赔数据库,本研究的目标是确定CHB患者非肝并发症的患病率和发病率以及CHB患者中并发症的预测因子。

研究患者和方法:患者是在第一次CHB诊断之前和之后的6个月持续覆盖(商业/医疗保险或医疗补助)的成年患者,配对非慢性乙型肝炎患者。分析Deyo-Charlson并发症指数(DCCI)和并发症(血管疾病、癌症、糖尿病、肥胖、高血压、高脂血症、酒精使用、肾脏损害、慢性肾脏疾病和骨质疏松/骨折)。

研究结果:本研究中纳入44026例CHB患者和121568例对照。对于商业/医疗保险,CHB患者的平均年龄从2006年的48.1±11.9到2015年的51.8±12.4岁;对于医疗补助,患者的平均年龄从44.1±11.1增加到50.2±10.2岁(两者都是P<0.001)。2006年商业/医疗保险中慢性肾脏疾病的流行率为36.1/1000,病例对照的慢性肾脏疾病的流行率为10.2/1000,在2015年分别增加到97.6和38.8。2006年CKD发病率(每-***年)为10.3和4.8;到2015年分别为15.2和11.3(P<0.05)。CKD的最有力的预测因素是:DM(HR:2.48),HTN(HR:3.29)和CVD(HR:2.61)(所有P<0.0001)。在骨质疏松/骨折疾病中,也可观察到相似的流行率和发生率变化。骨质疏松/骨折的最强烈的预测因素是女性(HR:2.22),酒精使用(HR:2.02)和病毒共感染(HR:1.37)(所有P<0.0001)。

研究结论:相比病例对照,被保险的CHB患者年龄较大,并发症越多,并且有较高的发病率和患病率。

原始出处


Nguyen MH, Lim JK, Ozba AB, et al. Advancing age and comorbidity in a United States insured population-based cohort of patients with chronic hepatitis B. Hepatology, 2018,  Sep 2. doi: 10.1002/hep.30246.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1825678, encodeId=30cf18256e8e4, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Dec 11 02:50:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807862, encodeId=7be1180e862ed, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Thu Apr 04 06:50:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758030, encodeId=41e81e580304f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Feb 20 05:50:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271280, encodeId=ca5912e12807f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427245, encodeId=9acc142e245c0, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620333, encodeId=b3b31620333dd, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1825678, encodeId=30cf18256e8e4, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Dec 11 02:50:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807862, encodeId=7be1180e862ed, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Thu Apr 04 06:50:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758030, encodeId=41e81e580304f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Feb 20 05:50:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271280, encodeId=ca5912e12807f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427245, encodeId=9acc142e245c0, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620333, encodeId=b3b31620333dd, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1825678, encodeId=30cf18256e8e4, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Dec 11 02:50:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807862, encodeId=7be1180e862ed, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Thu Apr 04 06:50:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758030, encodeId=41e81e580304f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Feb 20 05:50:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271280, encodeId=ca5912e12807f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427245, encodeId=9acc142e245c0, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620333, encodeId=b3b31620333dd, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2019-02-20 丁鹏鹏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1825678, encodeId=30cf18256e8e4, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Dec 11 02:50:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807862, encodeId=7be1180e862ed, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Thu Apr 04 06:50:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758030, encodeId=41e81e580304f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Feb 20 05:50:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271280, encodeId=ca5912e12807f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427245, encodeId=9acc142e245c0, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620333, encodeId=b3b31620333dd, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1825678, encodeId=30cf18256e8e4, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Dec 11 02:50:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807862, encodeId=7be1180e862ed, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Thu Apr 04 06:50:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758030, encodeId=41e81e580304f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Feb 20 05:50:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271280, encodeId=ca5912e12807f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427245, encodeId=9acc142e245c0, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620333, encodeId=b3b31620333dd, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]
    2018-09-27 gwc384
  6. [GetPortalCommentsPageByObjectIdResponse(id=1825678, encodeId=30cf18256e8e4, content=<a href='/topic/show?id=1a942339426' target=_blank style='color:#2F92EE;'>#乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23394, encryptionId=1a942339426, topicName=乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ea6321, createdName=okhuali, createdTime=Tue Dec 11 02:50:00 CST 2018, time=2018-12-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1807862, encodeId=7be1180e862ed, content=<a href='/topic/show?id=dd7d8124144' target=_blank style='color:#2F92EE;'>#肝炎患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81241, encryptionId=dd7d8124144, topicName=肝炎患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd0d217, createdName=huiwelcome, createdTime=Thu Apr 04 06:50:00 CST 2019, time=2019-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1758030, encodeId=41e81e580304f, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Wed Feb 20 05:50:00 CST 2019, time=2019-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1271280, encodeId=ca5912e12807f, content=<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53463, encryptionId=3d745346316, topicName=慢性乙型肝炎)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/iaP1mV9qBwx5tE2F4xcG1r4x1PibWvluIFLB8VsViakqNMBia2Z0wFibVrYwDEILvHB1OomzzTAAGy5MVl5BrdEv9Bw/132, createdBy=e11f100, createdName=guguangxiang, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1427245, encodeId=9acc142e245c0, content=<a href='/topic/show?id=221d685172' target=_blank style='color:#2F92EE;'>#EPA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6851, encryptionId=221d685172, topicName=EPA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4a9b4077760, createdName=gwc384, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1620333, encodeId=b3b31620333dd, content=<a href='/topic/show?id=6a2f3e9132a' target=_blank style='color:#2F92EE;'>#发病年龄#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37913, encryptionId=6a2f3e9132a, topicName=发病年龄)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=973220095439, createdName=showtest, createdTime=Thu Sep 27 09:50:00 CST 2018, time=2018-09-27, status=1, ipAttribution=)]

相关资讯

Clin Transl Gastroenterol:慢性乙型肝炎患者并发症增加

CHB患者的年龄正在老龄化,呈现出更多的并发症。为了预防和减轻肝脏和非肝病的并发证,需要早期诊断和治疗。

《2018年美国肝病学会乙型肝炎指导:慢性乙型肝炎预防、诊断和治疗(更新)》摘译

2018 年美国肝病学会(AASLD)的乙型肝炎指导旨在补充2016 年AASLD 的慢性乙型肝炎治疗实践指南并更新2009 年以来的HBV 指南。2018 年AASLD 的乙型肝炎指导在乙型肝炎患者筛查、预防、诊断以及临床管理方面提供了数据支持性的策略。与2016 年指南不同的是,2018 年指导未行系统评价,亦未应用GRADE 分级系统评价证据质量和推荐强度,而是基于以下几个方面由专家组共识发

病例分享:权衡,抉择!惟愿她的青春不留遗憾

本例患者为26岁女性,未来有怀孕或生育的可能,有停药需求。既往服用拉米夫定2年耐药,换用替比夫定联合阿德福韦治疗虽然HBeAg阴性、HBV DNA≤1000 copies/ml,但HBsAg仍为阳性(465.5 IU/ml定量)。这类低病毒载量、HBeAg阴转和HBsAg定量低水平是NA经治Peg-IFN优势人群的临床特征,而根据上文所提及的指南/共识、临床研究证据,对优势人群开展Peg-IFN治

二维剪切波弹性成像评估慢性乙型肝炎肝纤维化临床应用指南

结合我国慢性乙型肝炎发病率高的现状,中华医学会超声医学分会介入超声学组组织了基于二维剪切波弹性成像技术(SSI)的"二维剪切波弹性成像评估慢性乙肝肝纤维化中国多中心研究",并在此研究成果的基础上,结合最新文献研究报道,对2D-SWE的临床应用进行广泛讨论并形成此共识,以期为超声同行及临床医务工作者提供最新的指导文献。

2018美国肝病学会慢性乙型肝炎预防诊断及治疗指导意见解读

2018 年美国肝病学会(AASLD) 更新了慢性乙型肝炎(CHB) 临床诊治指南,形成了新的指导意见(guidance),并发表在AASLD 官方杂志Hepatology 上。2018 AASLD 的CHB guidance 主要在 CHB 预防、诊断以及治疗,特别是特殊人群治疗方面进行了更新。文章结合美国肝病学会前主席Anna S LOK 教授在2018 亚太肝病年会大会的报告,重点对指导意见

2018 AASLD指南:慢性乙型肝炎的预防,诊断和治疗(更新版)

2018年美国肝病学会(AASLD)的乙型肝炎指南旨在补充2016年AASLD的慢性乙型肝炎治疗实践指南并更新2009年以来的HBV指南。2018年AASLD乙型肝炎指导在乙型肝炎患者筛查、预防、诊断以及临床管理方面提供了数据支持性的策略。